Two recent cases mana ged at the University ofCalifornia San Diego (UCSD) Nasal Dysfunction Clinic are described, with a review of the sinu s computed tomography (CT) findin gs of six common unilateral sinona sal conditions. These include the homogeneous app earance and absenc e ofbony destruction characteristic of unilateral beni gn polyposis, thefocal hyperintensities ojfungal sinusitis, the septal bowing seen in invertin g papilloma, the involvement of the ptery gopalatin e fo ssa by an angiofibroma, the cribifo rm plate dehiscence associated with an encephalocele/meningocele and the extensive bony destru ction characteristic of malignan cy, such as epidermoid carcinoma. The clinical appe arance and salient sinus CTfeatu res may suggest the diagnosis, thereby decreasin g the morbidity fro m invasi ve tests, such as biopsy of an angiofibroma or an encephalocele, and improving quality resour ce mana gement.
Two recent cases managed at the University of California San Diego (UCSD) Nasa l Dysfunction Clinic brought the importance of an accurate diagnosis to our attention. In addition, the se cases were the stimulus to review the typic al CT finding s of unilateral sinonasal masses in an attempt to define and diagno se them by CT and clinical appearance alone.
Case Reports Case 1
A 23-y ear-old woman was seen with a six-month history of progressivel y wor sen ing left nasal obstruction and a one-month history of right nasal obstruction. Thi s was accompanied by facial pressure over the left cheek region, a yellow nasa l disch arge , snoring and voice character changes. Three years before, she had sustained a severe closed head injury in an automobile accident with result ant anosmia. She den ied pain, persistent coug h, allergy or prior sinus disease .Physical examination revealed a smooth, fleshy mass visible in the left anter ior naris and the absence of soft palate elevation with phonation. The remainder of the head and neck examination was unremarkable.
Non-contrast sinu s CT imaging ( Figure I ) reve aled a large , hom ogeneous mass involving the entire left nasal cavity, left maxi llary and ethmoid sinuse s, and posterior nasal cav ity. There was no evidence of bone destruction.
Given the history of closed head traum a and the concern for an encephaloce le, biopsy was deferred and an MRI perform ed. The Tl -weighted image confirmed a large massthro ughout the left nasal ca vity, maxill ary sinus and ethmoid sinus with a low signal densit y; the signal density was, however, gre ater than that of cerebrospinal fluid (CSF). The T2-weighted image showed an incre ased signal intensity throu ghout the mass. The re was peripheral enhancement in a mucosal pattern and no ev idence of bone destruction.
Because the pat ient was young, the Tl MR image was sugges tive of a fluid with high protein content, such as blood , and because a neuroradiologist beli eved this could ENT-Ear, Nose & Th ro at Journal " January 1999 SPECIFIC DESIGN FEATU RE S • Aerofoil haped base for joint decompression.
• Double mo uthguard effect limit bruxi ng.
• Single size for all pat ients.
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SNORER VERSION
The majority of intra o ra l snoring devices tend to be contraindica ted in TMJ/D cases as they hold the condyles in a fixed pos ition whic h is hard o n the joi nts. T his ca n precipitate a T MJID ac ute phase. The TM J App liance 's 'Snorer Version' has a 8mm hole in the front to treat selected snoring and sleep diso rders in conjunction with TMJ /D trea tment and prevention.
TMJ/D PATIE TS
A T IMMEDIATE SYMPTOM RELIEF not iust another referral T he TMJ Appl iance ® is a computer designed , pre-molded , dental splint, spec ifically developed for treatin g TMJ /D in the medical practice.
The pati ent tak es it o ut of the co nta iner, places it in their mo uth and an IMM EDIATE decr ea se in symptoms u ually occurs. be an angiofibroma, angiography was per formed . Th ere was no evidence of a vascu lar mass in the invo lved region. The patient subse quently underwent endosco pic sinus surgery with left sinonasa l mass resection . There was no bleeding and there were no CSF leakage co mplica tions. Surgical patho logy on frozen and permanent sec tion revealed benign nasa l polyposis.
OUT OF YOUR OFFICE WITH TREATMENT IN MINIMAL TIME

Case 2
A l 6-year-old boy was referre d with a presump tive diag nosis of ang iofibroma and a one-mon th history of right nasal obstruc tion and difficult y breathin g. He denie d epistaxis . Physical exa mination revealed a pinkis h-red, round mass in the right anterior naris, visible in the nasopharynx on mirror exa mination. In add ition, there was 2 to 3 mm proptosis of the right eye, distortion of the right medial canthus and broaden ing of the nasal bone.
Sinus CT imagin g ( Figure 2 ) revealed a soft-tissue mass filling the right nasa l cav ity and max illary , ethmoid and sphenoid sinuses . The nasal sept um was bowe d to the left, and there was evidence of bone destruction of the lateral nasal wa ll. Th ere were several foca l areas of mottled hyperintensity.
Although angiofibroma is a possibility in a pubescent boy, the clinical appe arance and lack of mass in the pterygopalatin e fossa ruled agai nst such an etio logy. After a needle aspiration found no blood, an anterio r punch biopsy was perform ed; the results were consistent with a benign nasal polyp. Durin g endoscopic sinus surgery resection of the rightsided mass, large co ncre tions were discovered . Surgical pathology reve aled hyphae suggestive of funga l sinusitis with no evide nce of mucosal invasion. A later culture iden tified the fungus as Drechslera. A literature searc h revealed only eleven previo us cases. !"
CT Findings Fungal Sinusit is
The most characteristic CT finding offunga l sinusitis is hyperdense foca l nodules, thought to represe nt collections of calcium phosphate or calcium sulfate in central necrotic areas." Such ext remely radiation-d ense areas have been noted in 50 to 100% of patien ts in three series ofconfirmed funga l sinusitis cases." !' Th ese hyperintense foc i can be quite large; in one serie s, the largest nearly formed a cas t of the maxillary sinus." Mucoperiosteal thickening may also be present , as funga l sin usitis is an inflamm atory process. Air-fluid levels are not usually seen." The soft-tiss ue appear ance may range from homogeneous to heterogeneous, with looping and cascading stro ma. CT may revea l sclerotic and thickened bones with reac tive osteitis, expansion of the sinus cav ities and/o r eros ion of the lateral nasal wall into the orbit with the potent ial for focal deforrnities.l':" Orbital involvement has been described as characteristic of the disease." Given the diverse soft-tiss ue and bon y changes, however, the hyperdense foca l nodules appear to be the most reliable CT finding indica tive of fungal sinusitis.
The CT image exa mple from Case 2 reveals a large, heterogeneous mass filling the right nasal cavity, right maxillary sinus and sphenoid and ethmoid sinuses. In the
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For more information Circle 105 on Reader Service Card BERR Y, DAVID SON superior aspec ts of the sinonasa l cavities, the mass is variega ted, with a dense, mottl ed appea rance and only minim al delineation of ethmoid cell wa lls. Loopin g stroma is visible in the se areas. In the inferi or aspects of the right maxillary sinus, the foca l hyperd ensities are more pronounced . There also are s mall area s of ex tre me hyperdensity within the maxillary sinus and nasal cavities not consis tent with disrupt ed bone pieces; these likely represent the calci fied nodules described above . Significant bone de stru ction of the lamina pap yracea (wi th displacement of the medial rectu s muscle), turbin ates, later al nasal wall and cribiform plate is visible . Portions of the turb inate bon es and nasal septum ca n be defin ed but show significa nt bowing and deform ity. Finally, the pte rygop alatin e fo ssa, which is often invol ved in angiofibrom a, is free of mass; this is a significa nt negative findin g, espe cially in a pubescent boy; i.e., this finding is not suspect for juvenile angiofibroma.
Benign Polyposis
Ben ign polypo sis, although more often bilateral, may be unilateral. Further confounding the diagnosis is the ability of polypoid sinusitis to cause orbital bony destruc-tion and proptosis, typical signs of malignancy ." :" More frequently, however, there is no invasion or bon y destruction. The walls of the sinonasa l cavities may eventually be expanded and thinn ed by the polyps.
A uniqu e CT finding is the appearance of cur vilinear strands of soft-tissue density that may descend from the superior aspects of the nasal vault or loop circumferentially around the main mass.l'':" Th is is not a co nsis tent finding; in one ser ies this loopin g co nfiguratio n, thou ght to repr esent polypoid exc rescences, was see n in only 16.4% of cases of proven beni gn polypoid sinusitis." Often, there may be a clear zone between the mass and the sinus wall, which is thought to be mucoid secretions. Although the clear zone and loopin g strands may be see n in fungal sinusitis as well, the focal areas of hyperintensity are unusual in beni gn polyposis.
The CT image from Case 1 shows a large, unil ateral, homo geneous mass filling the entire left nasa l cavity and the left maxillary sinus, with nearl y co mplete involvement of the left ethmoid and maxillary sinuses . Th e looping strands and clear zone of muc oid sec retions are abse nt in this exa mple. In addition, there are no areas of foc al hyperinten sity. Th e walls of the nasal cavity are 30 For more information Circle 106 on Reader Service Card ENT-Ear , Nose & Throat Journal" January 1999 RADIOLO GY OF UNILATER AL SINON ASAL OPACIFI CATION somewha t expanded by the mass, and bowin g of the anterior portion of the nasal septum is visible. Bony destru ction is abse nt; the details of the middle and inferior turbin ates are easi ly deli neated . Overall , the pic ture is one of a beni gn process originating in either the maxillary sinus or nasal cavi ty and com municating nond estru ctively along natu ral fora mina.
Angiofibroma
Angiofib roma s, most co mmo nly see n in pubes cent boys, may be recogni zed on CT image by their location. Clinical suspicion and early recognition are desirabl e, as biopsy may cause significant bleedin g. Typicall y, they appea r as a unilateral , homogeneous mass arising fro m the roof of the nasoph arynx, posteri or nasal fossa or sphe nopalatine foramen and extending into the ptery gopalatinefossa,":" So reliable is this charac teristic that a mass residin g prim arily in the nasal cavity with limited extension into the nasoph arynx and pterygopalatin e fossa is prob abl y not an angiofibro ma.
Anoth er notable CT findin g is anterior bowin g of the posteri or wall of the maxillary sinuses and posterior bow ing of the posteri or wa ll of the pterygop alatine fossa.1 9 . 2 1. 23.24 Th is was the most co nsistent find ing in a ser ies by Levine et al. ' ? The mass tend s to expand along natural planes and foramina and tend s to cause bony distorti on by pressure rather than destruction .18.23 Angiograph y is indicated to confir m the diagnosis, identify feeding vesse ls and evalu ate intracran ial extension. Figure 3 is a sinus CT image of a 16-year-old boy with a seve n-mo nth history of progressive left nasal obstruction, left-sided frontal headache, otalgia, tooth ache and a recent posteri or nosebl eed requiring a two-unit transfusio n. His sca n revealed a homo gen eous soft-tissue mass nearl y fillin g the left side of the nasopharynx and extending into the ptery gopalatine fossa with anterior bowing of the posterior wall of the left maxill ary sinus. The mass extended anteriorly into the midn asal cavity and inferiorly to the left eustachian tube.
Encephalocele/Meningocele
Enceph alocele should be suspec ted in a pat ient with deh iscence of the anterior cranial fos sa and a hom ogeneous nasal mass proximal to the dehi scent region . On CT image, the density of brain parenchym a is quit e similar to that of inflammatory and neoplastic processes; therefore , Maico has been assisting physicians for over 60 years in accurately diagnosing and monitoring middle ear diseases and related surgeries. Put your trust in Maico Products. the presence of a bony defect adjacent to a superior nasal cav ity soft -tiss ue mass is the clue to the proper diag nosis." The defect often occurs at the j unction of the orbita l portions of the fro ntal and ethmoida lbones." Because the integrity of the anterior cranial fossa may be lost or severely thin ned at the region of the cri biform plate, it is important to note the proximity of the mass to this area to determine if it passes thro ugh, or is simply adjacent to, the deh iscence. Small bony defects, on the othe r hand, may not always be vis ible and may lead to the misdiagnosis of the mass as a nasa l glioma, a tumor usua lly com pletely isolated fro m the central nervous system. If there is cli nical suspicion of an encep haloce le or meningocele, MRI is required .
MA 53 Two-Channel Audiometer
The sinus CT image example (Fig ure 4) is a 58-year-old wo man wit h a two -year history of clear right-sided rhinorrhea following resec tion of a right-sided "m ucoce le." There is a notable bony dehiscence in the right cribiform plate, with a smooth, homogeneous mass that appears to extend through the dehisce nce. Thi s was confirme d by MRI to be an encephaloce le.
Inverting Papilloma
Inverting papilloma are unilateral and almost exclusively arise from the lateral nasal wall," :" usually at a location posterior to the uncinate process and adjacent to the middle turbinate." They typically attenuate bone and enter the maxillary and ethmoid sinuses as a contiguous, homogeneous mass which, if large eno ugh, may exte nd posteriorly through the nasal choa na into the nasopharynx." An inverting papillom a that extends from the region of the middle mea tus to the maxillary sinus may be confused with a unilateral antrochoa nal polyp; however, small calcifica tions may be see n with the former .The lateral nasal wall, turbi nates and inferio r portion of the ethmoid bone are affec ted early, whereas bowing of the nasal septum is consi dered a late sig n. Erosion into the lamina papyracea, cribiform plate and hard palate are other late signs. Figure 5 is a sinus CT image of a 63-year-old woman with a two-year history of right-sided nasal co nges tion. A co ntiguous unilateral, homogeneous soft-tissue mass is seen in the right nasa l cavi ty, with extension into the maxi llary, ethmoid and frontal sinuses. The nasa l septum is bowed and the mass extends posterio rly into the nasophary nx. Bony portions of the lateral nasal wall and turbin ates are visible, although thinn ed. No calcification is seen. Surgical pathology diagnosed an inverting papilloma.
Carcinoma
The sinus CT appearance of malignant tum ors of the nose and paranasal sinuses is most notable for irreg ular margins and aggressive bone destruction.v-" Acco rding ENT-Ear, Nose & Throat Journal " January 1999 2 sprays per nostril twice dail y. In placebo-controll edefficacy trials, the incidence of discontinuation due to adverse reactions in patient s recei ving Astelin' Nasal Spraywas notsignificanlly different from vehicle placebo (2.2% vs 2.8%, respectively).
In these clinical studies, adverseevents thatoccurredstatistically significantly more often in patients treated with Astelin" Nasal Sprayversus vehicleplacebo included bitter taste (19.7% vs 0.6%) , somnolence (11.5% vs 5.4%), weight increase (2.0% vs 0%), and myalgia (1.5% vs 0%).
The following adverseevents were reported with frequ encies ,,2% in the Astelin' Nasal Spray treatmentgroup and more frequently than placebo in short-term ($2 days) andlong-term (2-8wee ks) clinical trials.
A fe/in~t~~· (azelastme Hel) 137meg
Respiratory: bronchospasm, coughing, throat burning, laryngitis. Special Senses: conjunctivitis. eye abnormality, eye pain, watery eyes, taste loss. Urogenit al: albuminuria, amenorrhea, breast pain, hematuria, increased urinary frequency. Whole Body: allergic reaction, back pain, herpes simplex, viral infection, malaise, painin extremi ties, abdominal pain.
In controlled trials involving nasal and oral azelastinehydrochloride formulati ons, there were infrequ entoccurrences of hepati c transaminase elevations. The clinical relevance of these reports has not beenestablished.
In addition, the foltowing spontaneousadverseevents have beenreportedduringthe marketing of Astelln" Nasal Sprayand may have no causal relationship with thedrug: anaphylactoid reaction, application site reaction, chest pain, condition agg ravated, confusion, diarrhea, dyspnea, facial edema, involuntary muscle contractio ns, par esthesia, parosmi a, pruritus, rash, tolerance, urinary retention, vision abnormal, and xerophthalmia. OVEROOSAGE There havebeen no reportedoverdosaqes with Astelin" Nasal Spray. Acute overdosage by adults with this dosage form is unlikel y to result in clinically significant adverseevents,other than increase d somnolence, since onebottle of Astelin' Nasal Spray contai ns 17 mg of azelasti nehydrochloride. Clinical studiesin adults with single doses of the oral formulation of azelast lnehydrochloride (up to 16 mg) have not resulted in increased inci dence of serious adve rse events. General supportivemeasures should be employed if overdosage occurs. There is no known antidoteto Astelln" Nasal Spray. Oral ingestion of antihistamines has the potent ial to cause serious adverse effects in young children. Acco rdingly, Astelin" Nasal Spray shouldbekept out of the reach of children. Oral doses greater than 120 mg/kg (480 times the maxim um recommend ed humandaily intranasal dose on a mg/m' basis) producedsignificant mortali ty in mice. Responses seen prior to mortali ty weretremor, convulsions, decreasedmuscle tone, and salivation. Single doses ashigh as10 mg/kg (270 times the maximum recommend edhumandai ly intranasal dose on a mg/m' basis) were well tolerated in dogs, but single doses of 20 mg/kg were lethal. DOSAGE AND ADMINISTRATION The recommendeddose of Astehn" Nasal Spray in adultsand children 12 yea rs and older is two sprays per nostril twice daily. Before initial use , the screwcap onthe bottle should bereplaced with the pump unit and thedel ivery system should be primed with 4 sprays or until a finemist appears. When3 or more days have elapsed since the last use, the pump should be reprimed with 2 sprays or until a fine mist appears. CAUTIO N: Avoid spraying In theeyes. Directions for Use: Illustrated patient instructions for proper use accompany each package of Astelin' Nasal Spray. HOW SUPPLlEO Astelin" (azelastinehydrochloride) Nasal Spray, 137 mcg (NDC0037-0241 -10) is supplie d asa package containinga total of 200 meteredsprays in two high-density polyethylene(HOPE)bottlesfittedwith screwcaps. A separate metered-dose spray pump uni t and a leaflet of pat ient instruclions arealso provided. The spraypump uni t is packaged in a polyelhylenewrapperand consistsof a nasal spray pumpfittedwith a blue safety clip and a blueplastic dust cover.
Each Astelin" (azelastinehydrochloride) Nasal Spray, 137 mcg, bottle contains 17 mg (1 mg/mL) of aze lastinehydrochloride to be used with thesupplied metered-dose spray pump unit. Each bottle can deliver 100 metered sprays. Each spraydelivers a meanof 0.137mL sol ution containing 137 mcg of azelastinehydrochl oride.
' P<O.05, Fisher's Exact Test (two-tailed)
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The followingevents wereobserved infrequently « 2% andexceeding placebo incidence) in pat ients whoreceived Astelin' Nasal Spray ( . Patient s should also be instructed to storethe bottle upright at roomtemperature with the pump tightl y closed out of the reach of children. In case of acci dentai ingestion by a youngchild, seek professional assistance or contact a poison control center immedi atel y.
Patients should beadvised agai nsttheconcurrent use of Astelin" Nasal Spraywith other antihistamines without consulting a physician. Pati ents who are, or may become, pregnant should betold that this product should be used in pre gnancyor during lactation only if the potenti al benefit justifies the potential risks to thefetus or nursing infant. Patient s should be advised to assess their individual res ponses to Astelin' Nasal Spraybefore engaging in anyactivity requiring ment al alertness, such as driving a car or operating machinery. Pati ents should be advised that the concurrent use of Astelm " Nasal Spraywith alcohoi or other CNS depressant s may lead to additionaireductions in alertness and impairmentof CNS performance and should beavoide d (see Drug Interactions). Drug Interactions: Concurrent use of Astelin? Nasal Spraywith alcohol or other CNS depressant s should be avoided because add itional reductions in alertness and additional impairment ot CNS performance may occur.
Cimet idine(400 mg twice daily) increased the meanCmax and AUC of orallyadministered azelastine hydrochloride (4 mgtwice daily) by approximately 65% . Ranitidinehydrochloride (150 mgtwice daily) had no effecton azelastinepharmacokinetics.
Interaction studies investigating the cardiaceffects, asmeasuredby thecorrected Of interval (OTc) , of concomitantly administered oral azelasti nehydrochlorideanderyt hromyci n or ketoconazole were conducted. Oral erythromycin (500mg three times daily for seven days) had no effect on azelastinepharmacokineti cs or QTc basedon analyses of serial electroca rdiograms. Ketoco nazole (200 mgtwice daily for 7 days) interfered with the measurementof azelastineplasma concentrations; however, noeffects on OTc were observed.
Nosigni ficant pharmacokineti c interaction was observed with thecoadministration of anoral 4 mg dose of azelastine hydrochl oride twice daily and theophylline 300 mg or 400 mg twice daily. Geriatric Use: U.S. placebo-controlled clinicaltrials included 11 patients above the age of 60years who weretreatedwith Astelin' Nasal Spray. Whilethis numberis verysmall and no substantialconclusions can be drawn, the adverse events in thisgroupweresimilar to patient s underage60 yea rs. Carcino genesis, Mutagenesis, Impairment of Fertility: Carci nogenicity studiesin rats and mice with oral azelastinehydrochl oride for 24 months at doses up10 30 mg/kg/day and 25 mg/kg/day, respectivel y (240 and 100 times the maximum recommend edhumandaily intranasal dose on a mg/m' basis), revealedno evi dence of carcinogenicity.
Azelastinehydrochlorideshowed no genotoxic effects in the Ames test, DNArepai r test, mouse lymph oma forward mutation assay, mouse micronucleus test, or chromosomal aberration test in rat bone marrow.
Reproduction and fertility studiesin rats showed no etfects on male or female fertility at oral doses of up to 30 mg/kg/day (240 times themaximumrecommend ed human dai ly intranasal dose on a mg/m' basis). At 68.6 mg/kg/day (550 times the maximum reco mmended humandai ly intranasal dose on a mg/m' basis), thedurati on of estrous cycleswasprolongedandcopulatory activity and thenumber of pregn ancies were decreased. The numbers of corpora lutea and implantations were decrease d; however, the implant ation ratio was not affected. Pregn ancy CategoryC: Aze lastinehydrochloride has been shown to be embryotoxic, fetotoxi c, and teratogeni c (external andskeletal abnormalities)in miceat an oral dose of 68.6mg/kg/day (280 times the maximum recommendedhumandaily intranasal dose on a mg/m' basis).
At an oral dose of 30 mg/kg/day (240 times the maximum recommended humandaily intranasal dose ona mg/m' basis), del ayedossification (undeveloped metacarpus), and theincidence of 14thrib wereincreased in rats. At 68.6mg/kg/day (550 times themaximum recommended human daily intranasal dose on a mg/m' basis) azelastinehydrochloridecaused abortion and fetotoxic effects in rats.
The rel evance to humans of these skeletal findings notedat only high drugexposurelevels is unknown.
There are no adequate andwell-controlled clinical studiesin pregnant women. Astel in' Nasal Spray should be usedduring pregnancy only if the potent ial benef it [ustities the potential risk to the fetus. Nur sing Mothers: It is not known whether azelastinehydrochloride is excreted in human milk. Because many drugsare excre tedin humanmilk, caution should beexercised when Asteli n' Nasal Spray is administered to a nursing woman . Pediatric Use: Safety and efficacy of Astel in' Nasal Sprayin pediatric patien ts below the ageof 12 yea rs havenot been establ ished. ADVERSE REACTIONS Adverse experience information for Astelin! Nasal Sprayis derived fromsix well-controlled, 2-dayto B-wee k clinical studies which included391 pati ents who received Astelin' Nasal Spray at a dose of The most commonly reported adverse events were bitter taste, somnolence, and rhinitis.
*Physician global evaluation of patients' need for additional therapy at end of study.
"There were no statistically significant differences between treatment groups in study 1 and 2; there was a statistically significant difference between treatment groups in study 3 (P=O.04). to Chow, the critical areas to be assessed fo r bo ny destruction in cl ud e the orbital wa lls , cribifonn pla te, fovea ethmoidalis, posterior wa ll of the maxi llary sinus, pterygo id pla tes and pterygopalatine fossa, and the wa lls of the sphenoid and fro ntal sin uses." Involvement of these regions indicates that the tumor is no longer co nfined to the nose and paranasal sinuses. In one series, bo ne destruction of the maxillary sin us wa ll was seen in 9 1% of confirmed cases of sq ua mo us ce ll carcino ma-of the pterygoid plate in 27 % and of the orb ital wa ll in 33 %.)1Less aggressive masses tend to cause bowing, expansion and thin ning of bony wa lls ra ther tha n destruct ion and, the refore, are less likel y to be ma lignant. T he use of a contrast mediu m usu all y is not be neficia l when evaluating sq uamous carci nomas of the nose and paranasal sinuses, because there is a somewha t simi lar en hancement of inflammatory processes, normal soft tissu e and ma ny be nign and ma lig nan t tumors.P:" Bo ny destruction, the refore, is the most reliable CT fin ding .
T he sinus CT sca n example ( Figure 6 ) is a sq uamous ce ll carcinoma in a 54-year-old man with a one-year history of progressive left facial pain and swelling , ep istax is, rhi norrhea and left nasal obstruction. The image reveals a heterogeneous mass aris ing from the left maxillary sinus, wit h extensive bony erosion of the anterior and medial sinus walls, the left side of the hard palate and the medi al wa ll ofthe left orbit. Th e mass destroys the vomer, extends pos ter iorly in to the Rosenmiillers fossa , invades the left ethmoid sinus and fills the sphenoid sin us . Finally, there is sclerosis of bone in the sku ll base. 
Summary
Uni lateral sinonasal masses are evaluated by pa tien t hi st ory, examinatio n and sin us CT scan. T he clinica l appearance and salient CT image features may suggest the diagnosis, thereby decreasi ng mor bidity from invasive tes ts and leading to more efficient use of resources.
Recognition of the characteristic patt ern of hyperdense focal nod ules and po ten tia l orbital invol vemen t sho uld be helpful for the early diagnosis of fungal sinusitis, whereas benign polyposis may be suggested by expansion of the sinuses, th inning of bony structures and, occasionally, by curvilinear soft-tissue strands .
Inverting papilloma and malignancy, such as epidermo id carcinoma, both develop aggressively and may cause significant facial distortion and pain. Inverting papilloma, however, is more often characterized by origin from the lateral nasal wa ll with bo ne atten ua tion and septal bowi ng, while carcinoma is diagnosed by striking bony destru ct ion.
Biopsy pro vides the necessary histopatho logic diagnosis , however, angiofibroma and encephalocele are two tumors in wh ich a biopsy should not be performed . Angiofibroma may be diagnosed re liably in a pubescent boy with a mass presen t in the nasopharynx and pterygopa latine fossa. If angiofibroma is of little concern, nee dle asp iration is performed before biopsy. A superior nasal cavity mass in proximity to a dehiscence in the floor of the Intended for the ma nagemen t an d treatm en t of p ost -ope ra tive bleedi ng and epista xis .
anter ior cranial fossa is the key to diagnosis of a meningocele or an ence phalocele. These tumors require MRI.
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